Cipla Ltd - CIPLA Share Price

Sector: Pharmaceuticals | ISIN: INE059A01026
₹ 1,404.05 (0.36%) icon18 May, 2024, 12:00:00 AM
Open
₹ 1,403.90
Prev. Close
₹ 1,399.05
Turnover(lac)
₹ 0.01
Day's High
₹ 1,407.30
Day's Low
₹ 1,400.25
52 Wk High
₹ 1,519.00
52 Wk Low
₹ 911.55
Book Value
₹ 355.65
Face Value
₹ 2.00
Mkt. Cap (Cr.)
₹ 113,362.29
P/E
30.42
EPS
46.00
Div. Yield
0.61

Cipla Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 5/18/2024 12:00:00 AM

    ₹ 1404.05 5.00 0.36
  • Open
  • ₹ 1,403.9
  • Prev. Close
  • ₹ 1,399.05
  • Turnover(Lac.)
  • ₹ 850
  • Day's High
  • ₹ 1,407.3
  • Day's Low
  • ₹ 1,400.25
  • 52 Week's High
  • ₹ 1,519
  • 52 Week's Low
  • ₹ 911.55
  • Book Value
  • ₹ 355.65
  • Face Value
  • ₹ 2
  • Mkt Cap (₹ Cr.)
  • 113,362.29
  • P/E
  • 30.42
  • EPS
  • 46
  • Divi. Yield
  • 0.61

Cipla Ltd Corporate Actions

05 Apr , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

03 Jan , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

03 Jan , 2024

12:00 AM

06 Nov , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

04 Oct , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

04 Oct , 2023

12:00 AM

11 Jul , 2023

12:00 AM

AGM

Announcement date: 11 Jul , 2023

View Details

04 Jul , 2023

12:00 AM

04 Jul , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

11 May , 2023

12:00 AM

Dividend

Dividend amount: 8.5
Announcement date: 11 May , 2023

View Details

No Record Found


Cipla Ltd News and Update

Image not found

On May 10, Cipla announced a 10% increase in revenue to ₹6,163 Crore and a 79% increase in fourth-quarter profit to ₹939 Crore.

Image not found

Cipla Buys Ivia Beaute's Beauty Brands for Rs 130 Crore

The deal is anticipated to close within 60 days after the BTA's signature, or on a later date that the parties have mutually agreed upon in writing.

  • 16 Apr, 2024 |
  • 11:04 AM
Image not found
  • 29 Jan, 2024 |
  • 12:29 PM
Image not found

Cipla’s Samina Hamied quits as executive vice chairperson due to personal commitments

The corporation claimed "personal and family commitments" as the reason for her departure from her present post.

  • 29 Jan, 2024 |
  • 12:23 PM

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Cipla Ltd SHAREHOLDING SNAPSHOT
18 May , 2024 | 06:14 PM

PROMOTER - TOTAL33.40%

Indian: 13.40%

Foreign: 19.9984%

NON-PROMOTER - TOTAL 66.39%

Institutions: 50.15%

Non-Institutions: 16.25%

CUSTODIES - 0.21%

Custodies: 0.21%

See More Details
ad IconAd Image

Cipla Ltd FINANCIALS

View Profit & Loss Graph

Cipla Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Cipla Ltd

  • Y K Hamied
  • Chairman (Non-Executive)
  • M K Hamied
  • Vice Chairman
  • S Radhakrishnan
  • Non-Exec & Non-Independent Dir
  • Ashok Sinha
  • Non-Exec. & Independent Dir.
  • Peter Mugyenyi
  • Non-Exec. & Independent Dir.
  • Adil Zainulbhai
  • Non-Exec. & Independent Dir.
  • Punita Lal
  • Non-Exec. & Independent Dir.
  • Samina Hamied
  • Executive Vice Chairperson
  • Umang Vohra
  • Managing Director & Global CEO
  • Rajendra Chopra
  • Company Sec. & Compli. Officer
  • Robert A Stewart
  • Independent Director
  • P R Ramesh
  • Independent Director
  • Mandar Purushottam Vaidya
  • Independent Director

Summary

Cipla Ltd is one of the leading pharmaceutical companies in India. The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). Ciplas product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. With a rich portfolio, it is deepening presence in the home markets of India, as well as South Africa, North America, and other key regulated and emerging markets. Its 47 manufacturing sites around the world produce more than 50 dosage forms and over 1,500 products across wide range of therapeutic categories. Cipla Ltd was incorporated in the year 1935 with the name Chemical, Industrial & Pharmaceutical Laboratories Ltd. Khwaja Abdul Hamied, the founder of Cipla gave the company all his patent and proprietary formulas for several drugs and medicines, without charging any royalty. On August 17, 1935, Cipla was registered as a public limited company with an authorized capital of Rs 6 lakh. From its first manufacturing unit at Bombay Central in 1936, Cipla now has over 40 state-of-the art manufacturing facilities across the globe including India, USA, China and South Africa.In the year 1941, as the Second World War cuts off drug supplies, the company starts producing fine chemicals, dedicating all its facilities for the war effort. In the year 1952, the company... Read More


Reports by Cipla Ltd


Reports by Cipla Ltd

Company FAQ

No Record Found